Transaction · 0001822629-26-000018

Lalwani Nikhil

Lalwani Nikhil, PRES, CEO, reported an open-market or private sale at ANI PHARMACEUTICALS INC involving 5400.000000 shares for an estimated $388206.00. Reported holdings after the transaction were 333689.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, CEO
ANIPANI PHARMACEUTICALS INC
Trade date
Oct 15, 2026
Filing date
Oct 16, 2026
View on SEC Insider profile
Estimated value-$388kShares × reported price
Shares traded5.40k$71.89 per share
Holdings after333kDirect
% of reported position traded1.59%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 339,089 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ANIP price since this filing

Daily closing prices, with the filing date and available return windows
ANIP · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.2%1w ago -0.4%1d ago -2.9%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001822629-26-000018
Common Stock
Transaction date
Oct 15, 2026
Filed Oct 16, 2026, 10:50 PM · 1d delay
Shares
5,400 sh
$71.89 per share
Estimated value
-$388k
Computed from shares × price
Holdings after
333,689 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

PRESIDENT & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.

  2. F2

    The shares were sold in multiple trades at prices ranging from $71.08 to $72.56. The price reported above reflects the weighted average sales price.

Original filing · 0001822629-26-000018
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ANIP